VolitionRx Limited (NYSE American: VNRX) has published the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company reports is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). The publication addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the large background of healthy cell-free DNA, thereby creating highly enriched tumor DNA datasets for cancer detection and monitoring. The company is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
The published research describes a two-step process combining physical sample enrichment with bioinformatic filtering to produce greater than 99% pure ctDNA sequencing datasets. Company scientists indicated that early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings. Volition is advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities.
The significance of this development lies in the potential to improve early cancer detection, which is critical for patient outcomes. The ability to isolate ctDNA with such high purity could lead to more accurate and sensitive liquid biopsy tests, enabling earlier diagnosis and better monitoring of treatment response. This is particularly important for cancers that are currently detected at advanced stages, where survival rates are lower.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, it is developing simple, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/.
To view the full press release, visit https://ibn.fm/nuJEs.
